These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19149702)

  • 1. Levosimendan for heart-operated patients: what is the state of the art?
    Tagarakis GI; Tsilimingas NB
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):22-4. PubMed ID: 19149702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical support and surgery of the failing heart: levosimendan.
    Toller W; Knez I
    Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353
    [No Abstract]   [Full Text] [Related]  

  • 10. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
    Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
    Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 13. Levosimendan for Perioperative Cardioprotection: Myth or Reality?
    Santillo E; Migale M; Massini C; Incalzi RA
    Curr Cardiol Rev; 2018; 14(3):142-152. PubMed ID: 29564979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM
    Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper.
    Farmakis D; Alvarez J; Gal TB; Brito D; Fedele F; Fonseca C; Gordon AC; Gotsman I; Grossini E; Guarracino F; Harjola VP; Hellman Y; Heunks L; Ivancan V; Karavidas A; Kivikko M; Lomivorotov V; Longrois D; Masip J; Metra M; Morelli A; Nikolaou M; Papp Z; Parkhomenko A; Poelzl G; Pollesello P; Ravn HB; Rex S; Riha H; Ricksten SE; Schwinger RHG; Vrtovec B; Yilmaz MB; Zielinska M; Parissis J
    Int J Cardiol; 2016 Nov; 222():303-312. PubMed ID: 27498374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of Levosimendan in intensive care treatment of myocardial insufficiency].
    Rehberg S; Ertmer C; Van Aken H; Lange M; Bröking K; Morelli A; Westphal M
    Anaesthesist; 2007 Jan; 56(1):30-43. PubMed ID: 17131137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: from basic science to clinical practice.
    Parissis JT; Rafouli-Stergiou P; Paraskevaidis I; Mebazaa A
    Heart Fail Rev; 2009 Dec; 14(4):265-75. PubMed ID: 19101796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.